INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

Advanced and/or Metastatic Solid Tumors Clinical Trial

Official title: A Phase 1b Combination Study of INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose of INCMGA00012 in combination with common standard-of-care chemotherapy regimens in participants with advanced solid tumors.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Advanced and/or Metastatic Solid Tumors
• Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma
• Carcinoma, Non-Small-Cell Lung
• Mesothelioma
• Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer

• NCT number: NCT03920839
• Study type: Interventional
• Source: Incyte Corporation
• Status: Withdrawn
• Phase: Phase 1
• Start date: July 15, 2019
• Completion date: November 4, 2019